Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Catabasis Pharma
(NQ:
CATB
)
2.810
USD
-0.060 (-2.09%)
Official Closing Price
Updated: 7:34 PM EST, Mar 5, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Catabasis Pharma
< Previous
1
2
3
4
5
6
Next >
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
March 02, 2021
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
From
Business Wire News Releases
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
January 29, 2021
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
From
Business Wire News Releases
Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid Leukemia
December 03, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid Leukemia
December 03, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
November 12, 2020
Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
From
Business Wire News Releases
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
October 26, 2020
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
From
Business Wire News Releases
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Societ
September 28, 2020
Catabasis Presents Information on Edasalonexent at the Virtual 25th International Congress of the World Muscle Society
From
Business Wire News Releases
Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society
September 23, 2020
Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society
From
Business Wire News Releases
Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
September 21, 2020
Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
From
Business Wire News Releases
Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
September 08, 2020
Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
From
Business Wire News Releases
Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
September 02, 2020
Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
From
Business Wire News Releases
Thinking about trading options or stock in CryoPort Inc, Catabasis Pharmaceuticals Inc, Wayfair, Novavax, Inc., or Thermo Fisher Scientific Inc.?
August 24, 2020
InvestorsObserver issues critical PriceWatch Alerts for CYRX, CATB, W, NVAX, and TMO.
From
PR Newswire
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
August 10, 2020
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
From
Business Wire News Releases
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
August 05, 2020
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
From
Business Wire News Releases
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
August 04, 2020
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
From
Business Wire News Releases
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
July 27, 2020
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
From
Business Wire News Releases
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
July 15, 2020
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
From
Business Wire News Releases
Catabasis Joins Russell 3000® Index
June 29, 2020
Catabasis Joins Russell 2000® Index
From
Business Wire News Releases
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
June 12, 2020
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
From
Business Wire News Releases
Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
May 12, 2020
Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
From
Business Wire News Releases
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy
May 12, 2020
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy
From
Business Wire News Releases
Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th
April 28, 2020
Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th
From
Business Wire News Releases
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
April 17, 2020
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
From
Business Wire News Releases
Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020
April 06, 2020
From
ACCESSWIRE
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
March 25, 2020
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference.
From
Business Wire News Releases
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
March 24, 2020
From
ACCESSWIRE
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session
March 18, 2020
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session
From
Business Wire News Releases
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress
March 10, 2020
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress
From
Business Wire News Releases
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th
February 25, 2020
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th
From
Business Wire News Releases
Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy
February 21, 2020
Catabasis Pharmaceuticals to present edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.